Atrium Therapeutics, Inc. RNA R2KR3KPHARMA
Company Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 38.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $18.62M (+70.9% YoY); net profit $-76.68M.
- Trailing 12 Months Year-on-year growth — revenue -21.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 38.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 38.09% |
| 1 Year: | -21.90% |
Stock Price Performance
| 1 Year: | -44.41% |
| 6 Months: | -39.21% |
| 3 Months: | -29.13% |
| 1 Month: | +0.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- RSI (14)42.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 38.1% over 5 years.
CONS
- Trading 50.4% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNA Atrium Therapeutics, Inc. R2KR3KPHARMA | 8.20 | -1.51 | $140.27M | 0.00% | -32.47% | -36.99% | 38.09% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 2.97M | 1.57M | 859.00K | 19.64M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 47.22M | 9.03M | 48.89M | 36.91M |
| Operating Income | -44.25M | -7.45M | -48.03M | -17.28M |
| EBITDA | -44.19M | -7.40M | -47.91M | -17.13M |
| Interest Expense | - | - | - | - |
| Pretax Income | -44.24M | -7.45M | -48.03M | -16.63M |
| Tax Provision | 1.95M | - | 34.00K | - |
| Net Income | -46.20M | -7.45M | -48.07M | -16.63M |
| Diluted EPS | - | -0.44 | - | -0.97 |
| R&D Expense | - | 6.94M | - | 16.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 9.76M | 10.90M | 18.62M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 16.15M | 24.11M | 95.43M |
| Operating Income | -6.39M | -13.22M | -76.81M |
| EBITDA | -6.25M | -13.05M | -76.49M |
| Interest Expense | - | - | - |
| Pretax Income | -6.38M | -13.22M | -76.83M |
| Tax Provision | 0 | 11.91M | -142.00K |
| Net Income | -6.38M | -25.12M | -76.68M |
| Diluted EPS | -0.37 | -1.47 | -2.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 10.29M | 7.19M | 278.35M |
| Current Assets | 856.00K | 483.00K | 272.85M |
| Cash & Equivalents | - | - | 270.00M |
| Inventory | - | - | - |
| Receivables | 751.00K | 0 | - |
| Total Liabilities | 80.91M | 68.29M | 71.07M |
| Current Liabilities | 33.80M | 26.80M | 41.80M |
| Long Term Debt | - | - | - |
| Total Debt | 9.85M | 6.80M | 3.67M |
| Total Equity | -70.62M | -61.11M | 207.29M |
| Shares Outstanding | 17.11M | 17.11M | 17.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 56.39M | -22.55M | -41.13M |
| Investing Cash Flow | -320.00K | -266.00K | -1.45M |
| Financing Cash Flow | -56.07M | 22.82M | 42.57M |
| Capital Expenditure | -320.00K | -266.00K | -1.45M |
| Free Cash Flow | 56.07M | -22.82M | -42.57M |
| Net Change in Cash | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -65.4% | -121.3% | -412.6% |
| Net Margin % | -65.4% | -230.5% | -411.9% |
| ROE % | 9.0% | 41.1% | -37.0% |
| ROCE % | 27.2% | 67.4% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sessa Capital IM, L.P. | 8.77% | 1.50M | $12.60M |
| 2 | Price (T.Rowe) Associates Inc | 8.61% | 1.47M | $12.37M |
| 3 | Blackrock Inc. | 8.46% | 1.45M | $12.16M |
| 4 | CRCM LP | 7.50% | 1.28M | $10.78M |
| 5 | Vanguard Capital Management LLC | 4.27% | 730.83K | $6.14M |
| 6 | TIG Advisors, LLC | 3.28% | 561.53K | $4.72M |
| 7 | Geode Capital Management, LLC | 2.26% | 386.93K | $3.25M |
| 8 | Two Sigma Investments, LP | 2.02% | 345.48K | $2.90M |
| 9 | Goldman Sachs Group Inc | 1.81% | 310.34K | $2.61M |
| 10 | 683 Capital Management LLC | 1.75% | 300.00K | $2.52M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNA
Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBnamxsZDVWeUMtd05sMmdYakt6NUVVdkl6eEJpZ2lLd3c2VHdUbHBlaDYwSjdUbmVmUjM4X25lbkxuQUw1c0tXeWRGbXhZS0ZQ?oc=5" target="_blank">Atrium Therapeutics, Inc. (RNA) Stock Price, News, Quote & …
RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE92QUNLMWJOSmlEaTM0Z3J6LWt3eVltYnNSRGItT2VULVlCYzNPLUZjRFRkbVZoNEx3NUJpMnhhSTBzaVZkQjNpQQ?oc=5" target="_blank">RNA: Atrium Therapeutics Inc. Latest Stock Price, Analysis, News and …
Atrium Therapeutics, Inc. (RNA) stock price, news, quote and history - Yahoo Finance UK
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFBnbGhoci1pV2pRcmVMM2hqaWt3Y0FEVTA4ZmxSY2hFVVRvYmk2R01WQVVqVTFCMFc1a2Z6Sm40bjNCdFdlUXI1aFVyOVlHU09l?oc=5" target="_blank">Atrium Therapeutics, Inc. (RNA) stock price, news, quote an…
Atrium Therapeutics is a buy, this analyst says - Cantech Letter
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQMFlPV0x1R1E0WDBjWVgzNFkyRGtMb0hCLXdMWE1xWV9TaG9tZGplaEE3aGc1cjRWdkZZeWlCMWhVSFZ5dDJDZzl3eU1oeTlzOEtkSkMteUQ5RDJkNnpPZGc3V0NPOXgyS3h1VWlDLTRUOXdEV0p1emMyYlVYYjZJVF9jdzQ1MEktU0dqZE…
Roth/MKM initiates Atrium Therapeutics stock with buy rating - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZjRQV1FULTVxTnNCSGxXU281dzdhT21YaC1wQlQ0MWpWQUZQc3JFaVNOWmlPN3I0TXduSVNSaUdySUp0dy1OWDJlM0hTR0g4X2UyV29NQ0FHX2RXc0hVUmhMRjFGWWJuYVhta0hjUkotc0xFd3Zmakplb0pRUloyUE5VVlhzUlJ5MnhrVn…
RNA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE9UR0g3Yks4azFOMUZwVXhzZkRLcmNpRC13Mm03cndTR1F0bTVkeDQ0SXRqXzdzWi1MakVkcWttZnd1TGFfTVVENW11dTBEQ0pWakttbGdYMm9DelBLaVJ3NEJNczgwVUNnTlZlOU11aTJhYWxBMmlWMg?oc=5" target="_blank">RNA F…
RNA — Frequently Asked Questions
What is the current share price of Atrium Therapeutics, Inc. (RNA)?
As of 2026-10-23 16:27 PDT, Atrium Therapeutics, Inc. (RNA) trades at $8.20 on NasdaqGS. Its 52-week range is $7.61 to $16.54.
What is the market capitalisation of RNA?
Atrium Therapeutics, Inc. (RNA) has a market capitalisation of $140.27M on NasdaqGS.
What is the P/E ratio of RNA?
RNA trades at a trailing price-to-earnings (P/E) ratio of -1.51. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 0.71.
What is the return on equity (ROE) of RNA?
RNA has a return on equity (ROE) of -36.99%. Its return on capital employed (ROCE) is -32.47%.
Is RNA a good stock to buy?
This page provides a data-driven analysis of Atrium Therapeutics, Inc. (RNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.